SenzaGen AB (SENZA) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to SenseAgent's presentation of the first quarter of 2025. My name is Rodnar Löhn and I am the advisor at Halvarsson. I am the CEO of the company, Peter Nellstedt, who will soon start his presentation. After that, we will start a Q&A session that I lead. There will also be an opportunity for those of you who are watching to ask questions if you think about 4.5. Peter, welcome. Thank you very much, Rodney, and welcome from my side as well to the Q1 presentation. I am the CEO of Sensagen, and we are building a future where what we did with animal testing earlier can now be done without animal testing, without animal-free methods, which we are building on high-tech solutions that we have developed. And this presentation will focus a lot on quarter one, how we have delivered financially. We will break down a little bit this performance in quarter one to how Guard, which is our core business, goes. And how we work to strengthen VitroScreen as an acquisition we carried out a couple of years ago. I will then, for any new investors, describe Sensagen and how we were going to grow in the future, especially with focus on our R&D pipeline. But to go back to quarter one. It has been an incredibly highly active quarter from our side. Vi har jobbat mycket hårt med vår försäljningspipeline och våra R&D-projekt och byggt och fått till många byggstenar i bolagsbygget för framtida tillväxt. Men vi har också verkat i en turbulent omvärld och det har i viss mån påverkat oss. If we look at sales results and Q1 results, then our sales growth is somewhat lower than we expect ourselves. We are back 5% in Q1, and that is due to the fact that we have a slightly different channel mix. We also have a relatively high volatility on the market, which we see has led to the customers taking ...